FDA awards 11 grants for rare disease treatment development

The U.S. Food and Drug Administration awarded 11 new clinical trial research grants to support the development of medical products for patients with rare diseases, according to a press release.

The Orphan Products Grants Program grants will distribute more than $25 million of funding over the next 4 years.

“Supporting the development and evaluation of new treatments for rare diseases is a critical part of the FDA’s mission,” said Acting FDA Commissioner Janet Woodcock, MD, in a press release. “These grants are the latest examples of the FDA’s ongoing commitment to help meet the future and current health needs of those who suffer from a rare disease.”

Michael B. Jordan, MD of Cincinnati Children’s Hospital Medical Center was awarded a grant of $3.1 million over 4 years for the Phase 2 study of abatacept for the treatment of common variable immunodeficiency with interstitial lung disease (ABCVILD).

View a complete list of grants here.